<DOC>
	<DOCNO>NCT01557374</DOCNO>
	<brief_summary>Ever since biotherapy agent enter market , recommend therapeutic objective Rheumatoid arthritis , remission . Once obtain , advise try reduce cease biotherapy agent , , efficacy counterbalance tolerance medium long term well high price . Nevertheless , dispose considerable data risk relapse structural progression step strategy . A study anti-TNF agent show possibility therapy reduction . A national study , `` STRASS `` , coordinate Bruno FAUTREL , evaluate possibility space even stop injection anti-TNF ( ) . To date , data concern Abatacept Tocilizumab publish . As expect result , study aim test feasibility step strategy 2 biological agent , Abatacept Tocilizumab , RA patient remission .</brief_summary>
	<brief_title>TOward Lowest Effective DOse Abatacept Tocilizumab</brief_title>
	<detailed_description>Ever since biotherapy agent enter market , recommend therapeutic objective Rheumatoid arthritis , remission . Once obtain , advise try reduce cease biotherapy agent , , efficacy counterbalance tolerance medium long term well high price . Nevertheless , dispose considerable data risk relapse structural progression step strategy . A study anti-TNF agent show possibility therapy reduction . A national study , `` STRASS `` , coordinate Bruno FAUTREL , evaluate possibility space stop injection anti-TNF ( ) . To date , data concern Abatacept Tocilizumab publish . This Non inferiority , prospective , randomize , control study PROBE ( Prospective Randomized , Open Blinded Evaluation ) evaluate method . The objective study : - For patient Rheumatoid Arthritis ( RA ) remission Abatacept Tocilizumab , evaluate term disease activity within 2 year period , impact progressive decreasing biotherapy strategy ( progressively space injection ) comparison usual treatment ( maintain usual dose injection frequency biotherapeutic agent ) . - To evaluate impact decrease strategy term RA relapse structural progression 1 2 year . - To determine cost-effectiveness ratio decrease comparison maintain biological treatment . Inclusion criterion : Patients RA , define ACR-EULAR 2010 criterion : - Treated least 1 year Abatacept Tocilizumab market authorize doses* , possibly DMARD ≤ 5 mg per day corticoid . - In remission least 6 month accord ACR/ EULAR 2010 remission criterion DAS 28 ≤ 2.6** Patients divide 2 group : 1 . Maintaining strategy : maintain biological treatment possibly associate DMARD corticoid . 2 . Decreasing strategy : decrease progressively biological agent via progressively increase injection interval , follow predetermined pattern , establish accord RA activity level , trimestrial visit . The primary judgment criterion : RA activity 2 year period time , measure repeat DAS44 . The secondary judgment criterion : - Percentage relapse 1 2 year . - Radiographic structural progression 1 2 year . - Cost-effectiveness ratio difference 2 strategy 2 year . As expect result , study aim test feasibility step strategy 2 biological agent , Abatacept Tocilizumab , RA patient remission .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Abatacept</mesh_term>
	<criteria>Patients least 18 year old . Patients RA , define ACREULAR 2010 criterion Treated least 1 year Abatacept Tocilizumab market authorize doses* , possibly DMARD ≤ 5 mg per day corticoid . In remission since least 6 month accord ACR/ EULAR 2010 remission criterion DAS 28 ≤ 2.6** Without destructive structural progression previous year hand foot xrays ( judge reference rheumatologist ) Informed study give acknowledge write consent participate study . Having prior medical visit . Prescribed dose stability ( space relate infection surgery prescribe dose spacing ) . An increase inflammatory parameter pain due intercurrent event must distinguish RA activity increase . Already include another treatment evaluation trial pathology . Surgical intervention program next 24 month come . Pregnancy 's anticipation next 24 month come . Non comprehension French language . Non affiliation social security . Patients legal guardianship .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Rheumatoid arthritis</keyword>
	<keyword>Disease activity</keyword>
	<keyword>Remission</keyword>
	<keyword>Lowest Effective DOse</keyword>
	<keyword>Abatacept Tocilizumab</keyword>
	<keyword>ACR-EULAR 2010</keyword>
</DOC>